Incyclix Bio is pushing forward with advanced precision therapies to take back command of the cell cycle where abnormal growth is a fundamental instigator of numerous cancers. We are convinced that the CDK family presents a plentiful wellspring of innovative cancer targets meriting pharmaceutical development. Our team is leveraging its unparalleled knowledge and profound expertise in CDK inhibitors to instill optimism in individuals grappling with advanced and resilient cancers. Irregular kinase activity of specific members within the CDK family propels unregulated cellular multiplication – a distinctive feature of cancer.